These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

63 related items for PubMed ID: 1327036

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Expression of the major surfactant-associated protein, SP-A, in type II cells of human lung before 20 weeks of gestation.
    Otto-Verberne CJ, Ten Have-Opbroek AA, De Vries EC.
    Eur J Cell Biol; 1990 Oct; 53(1):13-9. PubMed ID: 2076699
    [Abstract] [Full Text] [Related]

  • 23. Surfactant protein gene expressions for detection of lung carcinoma cells in peripheral blood.
    Yamamoto O, Takahashi H, Hirasawa M, Chiba H, Shiratori M, Kuroki Y, Abe S.
    Respir Med; 2005 Sep; 99(9):1164-74. PubMed ID: 16085219
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation.
    Jiang SX, Kameya T, Sato Y, Yanase N, Yoshimura H, Kodama T.
    Am J Pathol; 1996 Mar; 148(3):837-46. PubMed ID: 8774138
    [Abstract] [Full Text] [Related]

  • 26. Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.
    Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Hartmann C, Helfrich B, Gilman L, Folkvord J, Helm K, Miller YE.
    Cancer Res; 1996 Feb 15; 56(4):831-9. PubMed ID: 8631021
    [Abstract] [Full Text] [Related]

  • 27. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas.
    Yi ES, Harclerode D, Gondo M, Stephenson M, Brown RW, Younes M, Cagle PT.
    Mod Pathol; 1997 Feb 15; 10(2):142-8. PubMed ID: 9127320
    [Abstract] [Full Text] [Related]

  • 28. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
    Woenckhaus M, Merk J, Stoehr R, Schaeper F, Gaumann A, Wiebe K, Hartmann A, Hofstaedter F, Dietmaier W.
    Hum Pathol; 2008 Jan 15; 39(1):126-36. PubMed ID: 17949785
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Immunohistochemical localization of surfactant protein A in N-bis (2-hydroxypropyl) nitrosamine-induced lung tumors in rats.
    Sakai K, Kohri T, Mizunuma T, Ichinose T, Sagai M, Kishino Y.
    Tokushima J Exp Med; 1996 Jun 15; 43(1-2):55-9. PubMed ID: 8885689
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Immunoreactivity of surfactant-apoprotein in adenocarcinomas, large cell and small cell carcinomas of the lung.
    Kitinya JN, Sueishi K, Tanaka K, Katsuda Y.
    Acta Pathol Jpn; 1986 Sep 15; 36(9):1271-8. PubMed ID: 3024446
    [Abstract] [Full Text] [Related]

  • 34. Surfactant protein A detection in large cell carcinoma of the lung.
    Uzaslan E, Ebsen M, Stuempel T, Freudenberg N, Nakamura S, Costabel U, Guzman J.
    Appl Immunohistochem Mol Morphol; 2006 Mar 15; 14(1):88-90. PubMed ID: 16540737
    [Abstract] [Full Text] [Related]

  • 35. Bronchiolization of the alveoli in lung cancer: pathology, patterns of differentiation and oncogene expression.
    Jensen-Taubman SM, Steinberg SM, Linnoila RI.
    Int J Cancer; 1998 Feb 09; 75(4):489-96. PubMed ID: 9466646
    [Abstract] [Full Text] [Related]

  • 36. Immunohistochemical study of lung adenocarcinoma using monoclonal antibody for 60-kilodalton antigen in type II pneumocytes and nonciliated bronchiolar epithelial cells. Comparison with two antisurfactant apoprotein antibodies.
    Suehiro T, Maeda K, Sueishi K.
    Am J Clin Pathol; 1989 Aug 09; 92(2):150-8. PubMed ID: 2547307
    [Abstract] [Full Text] [Related]

  • 37. Immunohistochemical localization of pulmonary surfactant apoproteins in various lung tumors. Special reference to nonmucus producing lung adenocarcinomas.
    Mizutani Y, Nakajima T, Morinaga S, Gotoh M, Shimosato Y, Akino T, Suzuki A.
    Cancer; 1988 Feb 01; 61(3):532-7. PubMed ID: 3338020
    [Abstract] [Full Text] [Related]

  • 38. Carcinoma of type II pneumocytes. PAS staining as a screening test for nuclear inclusions of surfactant specific apoprotein.
    Singh G, Katyal SL, Torikata C.
    Cancer; 1982 Sep 01; 50(5):946-8. PubMed ID: 6178499
    [Abstract] [Full Text] [Related]

  • 39. The pathobiologic features of carcinomas of type II pneumocytes. An immunocytologic study.
    Singh G, Scheithauer BW, Katyal SL.
    Cancer; 1986 Mar 01; 57(5):994-9. PubMed ID: 2417691
    [Abstract] [Full Text] [Related]

  • 40. Papillary adenoma of type II pneumocytes might have malignant potential.
    Mori M, Chiba R, Tezuka F, Kaji M, Kobubo T, Nukiwa T, Takahashi T.
    Virchows Arch; 1996 Jun 01; 428(3):195-200. PubMed ID: 8688974
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.